What is the real cost of approved treatments for advanced prostate cancer and how much we should spend? These questions are rippling through the prostate cancer community and the general population. […]
Genetic counseling is common place in the world of breast cancer including the evaluation of the BRCA genes. Prostate and breast cancer increasingly been shown to have a relationship, perhaps all the down to the genetic level. Researchers are now understanding, that like in breast cancer, BRCA1 loss preexisting in small sub-populations of prostate cancer [...]
A group of researchers from the Dipartimento di Endocrinologia ed Oncologia Clinica e Molecolare, Università Federico II, Napoli, Italy wanted to know if retreatment with docetaxel could be tolerated and have a positive effect in men with castration-resistant prostate cancer (CRPC) who have already failed chemotherapy. The researchers evaluated 45 men who had initially responded [...]
Probably not. But we totally do have rough moments that often wipe away the most recent perfect moment in a heart beat. Definitely a topic worth talking about. And writing about. It was Jennifer Senior's New York Magazine article that started it all. Shout out to Jason, Paul, and Jennifer who along with me had [...]
Sanofi-aventis, the pharmaceutical company that makes taxotere and the newly approved drug, Jevtana (cabazitaxel) yesterday announced that their newly approved treatment for men with metastatic hormone-refractory prostate cancer (mHRPC) who have been previously treated with a docetaxel-based treatment regimen and failed is finally available for distribution in the United States. Around one month ago, Jevtana [...]